Tracked for
Impact Factor
Indexed in
Scopus
22 days
Time to First Decision

Pharmacoepidemiology, Volume 4, Issue 3

2025 September - 6 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

Select all

Article

1 Citations

2,497 Views

15 Pages

Suspected Adverse Drug Reactions Associated with Leukotriene Receptor Antagonists Versus First-Line Asthma Medications: A National Registry–Pharmacology Approach

Mohammed Khan,
Christine Hirsch and
Alan M. Jones

Pharmacoepidemiology2025, 4(3), 18;https://doi.org/10.3390/pharma4030018

19 September 2025

Background/Objectives: The aim of this study was to determine the suspected adverse drug reaction (ADR) profile of leukotriene receptor antagonists (LTRAs; montelukast and zafirlukast) relative to first-line asthma medications such as short-acting be...

Full Article

Article

5,904 Views

12 Pages

Metamizole as the Most Consumed Analgesic in Brazil During the COVID-19 Pandemic: Why Does It Matter?

Mayra R. C. de Souza,
Alciéllen M. da Silva,
Patrícia S. Bazoni,
Jéssica B. R. dos Santos and
Michael R. R. da Silva

Pharmacoepidemiology2025, 4(3), 17;https://doi.org/10.3390/pharma4030017

30 August 2025

Background: During the COVID-19 pandemic, analgesic use increased significantly, primarily due to self-medication for symptom relief. In Brazil, metamizole (dipyrone) is widely used despite international restrictions, highlighting the importance of e...

Full Article

Article

8,309 Views

10 Pages

Black Box Warning by the United States Food and Drug Administration: The Impact on the Dispensing Rate of Benzodiazepines

Neta Shanwetter Levit,
Keren Filosof,
Jacob Glazer and
Daniel A. Goldstein

Pharmacoepidemiology2025, 4(3), 16;https://doi.org/10.3390/pharma4030016

21 July 2025

Background/objectives: In 9/2020, the United States Food and Drug Administration )FDA( posted a black box warning for all benzodiazepines, addressing their association with serious risks of abuse, addiction, physical dependence, and withdrawal reacti...

Full Article

Review

2 Citations

6,054 Views

32 Pages

Prescribing Responsibly: Navigating the Tides of Deprescribing in Proton Pump Inhibitor Stewardship

Anna Peyton-Navarrete,
Minh Hien Chau Nguyen and
Alireza FakhriRavari

Pharmacoepidemiology2025, 4(3), 15;https://doi.org/10.3390/pharma4030015

9 July 2025

Proton pump inhibitors (PPIs) are widely prescribed medications primarily used to treat gastroesophageal reflux disease, peptic ulcer disease, and upper gastrointestinal bleeding. Despite clear therapeutic benefits in appropriate contexts, widespread...

Full Article

Systematic Review

1 Citations

9,748 Views

13 Pages

The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review

Jahnavi Udaikumar,
Rithish Nimmagadda,
Vindhya Vasini Lella,
Kesava Manikanta Achuta,
Satwik Kuppili,
Suraj Reddy Avula and
Raiya Sarwar

Pharmacoepidemiology2025, 4(3), 14;https://doi.org/10.3390/pharma4030014

27 June 2025

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcino...

Full Article